- Report
- December 2025
- 200 Pages
Global
From €2683EUR$2,990USD£2,341GBP
- Report
- December 2025
- 200 Pages
Global
From €7135EUR$7,950USD£6,224GBP
- Report
- May 2025
- 136 Pages
Global
From €4263EUR$4,750USD£3,719GBP
- Report
- June 2025
- 150 Pages
Global
From €2422EUR$2,699USD£2,113GBP
- Report
- July 2023
- 115 Pages
Global
From €3455EUR$3,850USD£3,014GBP
- Report
- May 2024
- 200 Pages
Global
From €3724EUR$4,150USD£3,249GBP
- Report
- October 2024
- 318 Pages
Global
From €7135EUR$7,950USD£6,224GBP
- Report
- May 2024
- 130 Pages
Global
From €3589EUR$3,999USD£3,131GBP
Neupro is a brand of central nervous system (CNS) drugs used to treat Parkinson's disease and restless legs syndrome. It is a dopamine agonist, meaning it works by activating dopamine receptors in the brain. Neupro is administered through a transdermal patch, which is applied to the skin and releases the drug over a period of time. The patch is designed to provide a steady, consistent dose of the drug throughout the day.
Neupro is a relatively new drug, having been approved by the US Food and Drug Administration in 2008. It is currently marketed by UCB, a Belgian biopharmaceutical company. Other companies in the CNS drug market include AbbVie, GlaxoSmithKline, Merck, and Pfizer. Show Less Read more
